Cargando…
Genetic markers in oligodendroglial tumours
BACKGROUND: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5–20% of all gliomas. CONCLUSIONS: Oligodendroglial tumours with 1p and 19q loss demonstrate a bett...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Versita, Warsaw
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423675/ https://www.ncbi.nlm.nih.gov/pubmed/22933885 http://dx.doi.org/10.2478/v10019-010-0007-y |
_version_ | 1782241126417170432 |
---|---|
author | Velnar, Tomaz Smrdel, Uros Popovic, Mara Bunc, Gorazd |
author_facet | Velnar, Tomaz Smrdel, Uros Popovic, Mara Bunc, Gorazd |
author_sort | Velnar, Tomaz |
collection | PubMed |
description | BACKGROUND: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5–20% of all gliomas. CONCLUSIONS: Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice. |
format | Online Article Text |
id | pubmed-3423675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Versita, Warsaw |
record_format | MEDLINE/PubMed |
spelling | pubmed-34236752012-08-29 Genetic markers in oligodendroglial tumours Velnar, Tomaz Smrdel, Uros Popovic, Mara Bunc, Gorazd Radiol Oncol Review BACKGROUND: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5–20% of all gliomas. CONCLUSIONS: Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice. Versita, Warsaw 2010-03-18 2010-03 /pmc/articles/PMC3423675/ /pubmed/22933885 http://dx.doi.org/10.2478/v10019-010-0007-y Text en Copyright © by Association of Radiology & Oncology http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Velnar, Tomaz Smrdel, Uros Popovic, Mara Bunc, Gorazd Genetic markers in oligodendroglial tumours |
title | Genetic markers in oligodendroglial tumours |
title_full | Genetic markers in oligodendroglial tumours |
title_fullStr | Genetic markers in oligodendroglial tumours |
title_full_unstemmed | Genetic markers in oligodendroglial tumours |
title_short | Genetic markers in oligodendroglial tumours |
title_sort | genetic markers in oligodendroglial tumours |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423675/ https://www.ncbi.nlm.nih.gov/pubmed/22933885 http://dx.doi.org/10.2478/v10019-010-0007-y |
work_keys_str_mv | AT velnartomaz geneticmarkersinoligodendroglialtumours AT smrdeluros geneticmarkersinoligodendroglialtumours AT popovicmara geneticmarkersinoligodendroglialtumours AT buncgorazd geneticmarkersinoligodendroglialtumours |